Articles

Highlights in melanoma

BJMO - volume 14, issue 8, december 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc, B. Neyns MD, PhD

At ESMO 2020, most attention in the melanoma field went to studies addressing the benefit of immunotherapy, alone or in combination with other drugs. First of all, updates on the use of immunotherapy in the adjuvant setting were provided for the Keynote-054 and the CheckMate 238 trials. In the advanced melanoma setting, several studies investigating combinations of immunotherapy with targeted agents will be addressed. In addition to this, the ILLUMINATE-204 trial investigates the potential of combining immunotherapy with intratumoral therapy. Similarly, a second study describes the value of local therapy in the treatment of solitary melanoma after progression upon checkpoint inhibitors. Finally, vaccination strategies with an IDO/ PD-L1 peptide vaccine and adjuvant dendritic cell vaccination will be discussed.

Read more

Highlights in respiratory oncology

BJMO - volume 14, issue 8, december 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc

At ESMO 2020, again many interesting studies in the field of respiratory oncology were presented. For non-metastatic non-small cell lung cancer (NSCLC), there was a focus on neoadjuvant immunotherapy, adjuvant treatment with osimertinib and post-operative conformal radiotherapy. When addressing metastatic NSCLC, much attention went to combination strategies such as combining EGFR and VEGF inhibitors, an EGFR-MET antibody plus a tyrosine kinase inhibitor or VEGF and PD-1 inhibitor combinations. In addition, the question was raised on whether immunotherapy can cure metastatic NSCLC. Finally, this overview will describe important results in the field of non-metastatic and metastatic small-cell lung cancer (SCLC).

Read more

Highlights in melanoma

BJMO - volume 14, issue 5, september 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc, B. Neyns MD, PhD

Summary

Over the last decade, the treatment of advanced melanoma underwent a dramatic improvement. Initially, immune checkpoint inhibitors and targeted agents proved their worth in the treatment of advanced, unresectable melanoma patients. More recently, however, interest grew in combining both these therapeutic approaches in patients with BRAF mutant advanced melanoma. During ASCO 2020, results were presented of two clinical trials evaluating this strategy. Following the initial successes in the unresectable melanoma setting, immune checkpoint inhibition and targeted therapy were also evaluated as adjuvant therapy in patients with resected stage III melanoma. At ASCO 2020, updated results were presented of two pivotal trials in this setting, while other studies looked into the potential benefit of using immune checkpoint inhibitors as neoadjuvant therapies, rather than in the postoperative setting. In addition to this, immunotherapy also proved to have potential in the treatment of patients with mucosal melanoma, or leptomeningeal disease.

(BELG J MED ONCOL 2020;14(5):209-15)

Read more

Highlights in breast cancer

BJMO - volume 14, issue 5, september 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc, H. Wildiers MD, PhD

Summary

During the 2020 Virtual ASCO meeting, no less than 226 presentations were dedicated to breast cancer. It is beyond the scope of this article to discuss all these abstracts, but instead we try to focus on the data that are most relevant for your daily clinical practice.

(BELG J MED ONCOL 2020;14(5):191-200)

Read more

Highlights in geriatric oncology

BJMO - volume 14, issue 5, september 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc, L. Decoster MD, PhD, H. Wildiers MD, PhD

Summary

Cancer is primarily a disease of older adults, and as a result improving the care for older patients with cancer is becoming increasingly important. In this respect, the 2020 virtual ASCO meeting featured a fascinating and very important session entitled “You’re only old once: improving outcomes for older adults with cancer.” In this session, positive results were presented of four randomised controlled trials evaluating whether or not geriatric assessment has the potential to improve treatment outcomes in older patients with cancer. Three of these trials focused on the geriatric management of patients receiving chemotherapy or other cytotoxic agents, while a fourth study evaluated to what extent perioperative oncogeriatric management could improve the outcome of patients undergoing surgery for gastrointestinal cancer. Overall, all these studies indicate that an integrated geriatric oncology assessment provides an important clinical benefit to older cancer patients.

(BELG J MED ONCOL 2020;14(5):218-21)

Read more

Highlights in gynaecological cancers

BJMO - volume 14, issue 5, september 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc, I. Vergote MD, PhD

Summary

The highlights in gynaecologic cancers from ASCO 2020 include data on the role of secondary cytoreductive surgery for women with recurrent ovarian cancer as well as several abstracts on the use of PARP-inhibitors in patients with platinum-sensitive relapsed ovarian cancer. In addition, several presentations focused on novel therapeutic strategies for patients with ovarian cancer, including immune-checkpoint inhibitors and the antibody-drug conjugate mirvetuximab soravtansine. Finally, the effectivity of sequential chemoradiation and the combination of the anti-PD1 antibody camrelizumab with the VEGF-targeting agent apatinib in patients with cervical cancer will be discussed.

(BELG J MED ONCOL 2020;14(5):227-32)

Read more

The 22nd annual BSMO meeting 2020

BJMO - volume 14, issue 4, june 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc

SUMMARY

On the 14th and 15th of February 2020, the Belgian Society of Medical Oncology (BSMO) organised the 22nd annual BSMO meeting in Ghent. At this meeting, medical oncologists, oncologists in training and other specialists involved in the management of cancer patients again had the opportunity to gather as a community, exchange ideas and engage in cooperation.

(BELG J MED ONCOL 2020;14(4):171–7)

Read more
X